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Insulin resistance in HCV mono-infected and in HIV/HCV
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2IBIM Consiglio Nazionale delle Ricerche, Palermo, ItalySee Articles, pages 684–692 and 712–718Insulin resistance (IR) is deﬁned as a condition in
which higher than normal insulin concentrations are
needed to achieve normal metabolic responses, or in
which normal insulin concentrations fail to elicit a nor-
mal metabolic response [1]. In recent years, diﬀerent
lines of evidence have found that IR is a common fea-
ture in patients with chronic hepatitis C (CHC) [2],
and is associated not only with host factors (visceral
obesity), but also with viral ones. Clinical studies have
found that HCV infection is an independent risk factor
for diabetes development [3], and, in particular, that
HCV-genotypes 1 (G1) and 4 are associated with IR,
identifying for these genotypes a linear relation between
the degree of IR and the viral load [4]. This has
prompted speculation that HCV, via up-regulation of
tumor necrosis factor-a (TNF-a), down-regulation of
suppressor of cytokine signaling, and the protein phos-
phatase PPA2, is able to interfere with insulin signalling
[5], in a context of complex molecular mechanisms in
which primitive metabolic disorders likely play a rele-
vant role.
The clinical relevance of IR in HCV infection arises
from its ability to act as a major disease-modiﬁer, con-
tributing to the severity of liver damage, and to interfere
with the response to antiviral therapy. The greatest evi-
dence for a determinative role of IR in CHC comes from0168-8278/$36.00  2009 European Association for the Study of the Liver.
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E-mail address: carlo.camma@unipa.it (C. Camma`).studies evaluating the inﬂuence of IR on ﬁbrosis. IR can
favor ﬁbrosis progression both directly and indirectly,
by inducing steatosis. IR, particularly in G1 patients,
represents the pathogenetic key of liver fat accumulation
[6], that is frequently reported as a factor independently
associated with the severity of ﬁbrosis in both cross-sec-
tional [6] and cohort studies [7], via generation of lipid
peroxids, stellate cell activation and collagenous deposi-
tion [8]. Similarly, several cross-sectional studies have
shown that IR evaluated by both HOMA and OGIS
(oral glucose insulin sensitivity), a more sensitive surro-
gate measure of IR), is directly associated with the sever-
ity of ﬁbrosis in CHC patients, independently of obesity
and liver steatosis [2,4,9–11].
The biological plausibility of this association resides
in the ability of insulin to stimulate hepatic stellate cells
and induce TNF-a and connective growth factor pro-
duction [12,13]. Hui et al. [9] ﬁrst identiﬁed the relation
between IR and severity of ﬁbrosis in a group of 283
patients with CHC derived from diﬀerent genotypes.
These data were subsequently conﬁrmed in two large
scale studies [4,10]. Moucari et al. [4] found this associ-
ation in 454 non-cirrhotic HCV patients, and Cua et al.
[10] identiﬁed IR as an independent risk factor for ﬁbro-
sis in a cohort of 346 HCV patients, also conﬁrming the
link in the sub-groups of both G1 (n = 186) and geno-
type 3 (G3) (n = 160) subjects. Similarly, in a homoge-
neous population of 201 nondiabetic European
patients with G1 CHC at low risk for the metabolic syn-
drome, we conﬁrmed that the presence of IR is associ-
ated with advanced ﬁbrosis [6], suggesting that in this
context overt type 2 diabetes further increases the risk
of severe ﬁbrosis [2].Published by Elsevier B.V. All rights reserved.
C. Camma`, S. Petta / Journal of Hepatology 50 (2009) 648–651 649Several recent studies have underscored the role of IR
in the development of advanced disease in HCV-infected
patients. First, IR was reported to be associated with the
presence of esophageal varices in a cohort of 104
patients with HCV-related Child-Pugh A cirrhosis [14],
suggesting the ability of insulin to interfere with both
ﬁxed (architectural disturbances) and dynamic (func-
tional alterations) components of portal hypertension.
Second, type 2 diabetes, the advanced expression of
IR, was identiﬁed as an independent risk factor for
hepatocellular carcinoma (HCC) in patients with HCV
infection [15], in keeping with the potential role of insu-
lin and IGF-1 in the carcinogenesis. Finally, steatosis, a
manifestation of IR, was independently associated with
HCC in patients with CHC in both cross-sectional [16]
and cohort studies [17].
Acorrect evaluationof the role of IR inCHCneeds fur-
ther attention, considering the potential use of insulin sen-
sitizing drugs (metformin, glitazones) in the management
of CHC, though caution is necessary. Two placebo-con-
trolled trials in NASH patients showed that pioglitazone
is able to improve ﬁbrosis [18,19]. In the same clinical set-
ting, similar results have been reported by Bugianesi et al
using metformin for one year [20]. By contrast, a recent
randomized placebo controlled trial in which NAFLD
patients received metformin for six months only, did not
conﬁrm a signiﬁcative histological improvement
[21].Unfortunately, all data on HCV patients originate
from cross-sectional papers, and the lack of prospective
studies remains an important limit in the assessment of
the role of IR in ﬁbrosis progression over time.At present,
the use of metformin or glitazones in HCV patients to
improve liver ﬁbrosis cannot be recommended, and long-
term, prospective, randomized trials are eagerly awaited.
Conversely, evidence of the role of IR in the development
of both portal hypertension (PH) and HCC is weak, and
comes from isolated reports for PH [14] or studiesmeasur-
ing surrogate markers of IR for HCC [15–17].
Contrasting data exist on the role of IR as a predic-
tor of sustained virological response (SVR) in the set-
ting of both HCV mono-infected and HIV/HCV co-
infected subjects. Romero-Gomez et al. [22] observed
that IR impaired SVR to peginterferon plus ribavirin
in 159 HCV mono-infected patients (mean age 41
years; 71% G1), and similar results were reported for
obese patients with HCV G2 or G3 infection in a paper
recently published in the Journal [23]. In addition,
Conjeevaram et al. [24] conﬁrmed the independent
association between IR and SVR rate in G1 African-
American and White-American infected patients with
a mean HOMA value ranging from 3.5 to 6.8. How-
ever, the evidence in the literature is not unequivocal.
As in recent reports [25,26], we could not conﬁrm a sig-
niﬁcant reduction in the response to combination ther-
apy in subjects with IR. In our setting [6], moderate/
severe steatosis, but not IR, was associated with alow likelihood of SVR in G1 HCV patients, emphasiz-
ing the importance of the degree of steatosis in inter-
feron unresponsiveness.
In this issue of the Journal, Dai et al. [27] report that
in Asiatic patients with G1 CHC, IR, but not steatosis,
was an independent predictor of poor response to anti-
viral treatment. A methodological issue of the current
study is the potential limitation of the generalizability
of its results to diﬀerent populations and settings, given
that the results were obtained in normal-weight Taiwan-
ese patients with normal cholesterol and triglyceride lev-
els, and low prevalence of steatosis (26%), all suggesting
a low risk for the metabolic syndrome. It should also be
remarked that this study included an easy-to-treat pop-
ulation with low mean viral load (500,000 UI/ml), low
prevalence of steatosis and severe (F3–F4) hepatic ﬁbro-
sis (14%). It should also be emphasized that in Taiwan-
ese patients, a population at high likelihood of response
to combination treatment, G1-infected subjects achieved
an SVR of 65% with a short course 24-week therapy.
In the same issue of the Journal, Merchante and col-
leagues [28] demonstrate in a retrospective study that
IR, assessed by the HOMA, is not a signiﬁcant predictor
of SVR to pegylated interferon plus ribavirin in a cohort
of 155 HIV/HCV co-infected patients at high prevalence
of IR. This study identiﬁes HCV genotype, viral load and
baseline LDL cholesterol levels as independent predic-
tors of SVR. Unfortunately, a methodological issue of
the study arises in the lack of data on steatosis as a poten-
tial predictor of SVR. In the setting of HIV/HCV co-
infected patients, after the introduction of antiretroviral
agents, the resulting reduction in morbidity and mortal-
ity has been accompanied to some degree by the develop-
ment of signiﬁcant metabolic andmorphological changes
[29]. Speciﬁcally, IR and diabetes have been found much
more common than in age- and BMI-matched non-HIV
controls [30]. The principal actor in these metabolic alter-
ations is thought to be HIV therapies. Mitochondrial
toxicity, alterations in adipose expression of genes
involved in adipocyte diﬀerentiation and lipid metabo-
lism, increased levels of proinﬂammatory cytokines and
reduction of adiponectin have been forwarded as the
most important putative pathophysiological mechanisms
involved in these alterations [29].
All the current available data raise one important
question: is IR, or the underlying steatosis, the cause
of low SVR?
The role of insulin sensitizers in mono-infected cases
is a matter of debate. In a recent trial, [31] pioglitazone
treatment associated with PEG-IFN plus RBV in
patients who were previously non-responders to stan-
dard therapy failed to elicit a satisfactory virological
response after 12 weeks of retreatment. Similar negative
results were reported by Romero-Gomez et al. [32] in a
randomized double-blinded trial, evaluating the eﬃcacy
of metformin with PEG-IFN plus RBV for 48 weeks in a
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negative results do not conﬁrm a direct interaction
between IR and low SVR, though a more prolonged
correction of IR, preceding the onset of antiviral ther-
apy, might be necessary to improve the SVR rate.
Regarding the role of steatosis as a predictor of SVR,
no studies have evaluated the potential eﬀectiveness of
fatty liver correction in increasing the likelihood of
response. To correct steatosis, the antiviral therapy
should be preceded by eﬀective lifestyle changes and
long-term use of insulin sensitizing drugs, though this
strategy could also fail in the presence of other cofac-
tors, and of steatogenic viral factors. Experimental and
clinical evidence suggests that HCV G3 is directly able
to induce steatosis [5], but similar eﬀects may also be
produced by G1 HCV [5]. There is also evidence of an
association between retinol binding protein 4 (RBP4)
and steatosis in G1 CHC patients, largely independent
of IR and metabolic factors, pointing to a possible direct
viral involvement in RBP4 abnormalities [33]. In this
setting, the correction of metabolic factors might not
necessarily result in an improved SVR rate, due to the
persistence of viral steatogenic mechanisms.
Concerning the issue of IR or steatosis as predictors
of SVR, we believe the available evidence is insuﬃcient
to give a deﬁnitive answer both in mono- and co-
infected patients. In fact, when a signiﬁcant heterogene-
ity in baseline characteristics of patients is found
between diﬀerent studies, caution must be exercised
when comparing results. Considering diﬀerent geo-
graphical and clinical settings, it is reasonable to specu-
late that both IR and steatosis could play an important
role in the achievement of an SVR.
In conclusion, the question of IR in both HCV mono-
and HIV/HCV co-infected subjects is far from settled.
The promotion of diet and life-style changes remains
mandatory, considering that weight loss can improve
liver ﬁbrosis in HCV mono-infected persons [34], but
pharmacological treatment of IR cannot be recom-
mended on the basis of available studies. What has been
learned about HCV and IR interaction in HCV mono-
infected patients could be probably applied in the setting
of HIV/HCV co-infected subjects, given that retroviral
therapy represents a further risk factor for IR develop-
ment, though, again, further data are needed.Acknowledgement
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